Treatment of difficulty or trouble in breathing with Unani medicine Laooq Zeequnnafas Balghami
- Conditions
- Mild intermittent asthma,
- Registration Number
- CTRI/2024/02/063365
- Lead Sponsor
- Central Council for Research in Unani Medicine CCRUM New Delhi
- Brief Summary
This study is designed as a single centric open trial in patients with Z**eeq un Nafas (Bronchial asthma)****.**After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria. The patients will be assessed clinically at every week for 4 weeks for improvement in patients with Bronchial Asthma. This includes subjective assessment of general well being and physical examination . The total duration of treatment will be 4 weeks. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.
**Composition of** ***Lauqe Zeequn Nafas Balghami***
| | | | |
| --- | --- | --- | --- |
|**S. No.**
**Ingredients**
**Botanical / Chemical Name**
**Quantity**
|
Asl- us - soos
*Glycyrrhiza glabra Linn.*
15 g.
|
Irsa (sausan)
*Iris ensata Thunb.*
15 g.
|
Gule Gaozaban
*Onosma bracteatum Wall.*
15 g.
|
Badiyan
*Illicium verum. Hook*
15 g.
|
Zufa E Kushk
*Hyssopus officinalis*
15 g.
|
Gul-e- Banafsha
*Viola odorata**Linn.*
15 g.
|
Unnab
*Ziziphus sativa Gaertn*
25 g.
|
Anjeer Zard
*Ficus carica Linn.*
25 g.
|
Maveez Munaqqa
*Vitis vinifera L.*
30g.
|
Tukhme Khatmi
*Althea officinalis Linn*
20 g.
|
Khubbazi
*Malva sylvestris*
20 g.
|
Parsiaoshan
*Adiantum capillus-veneris*
20 g.
|
Nabat Safed
*Sugar crystal*
1 kg
|
Asal
*Shorea robusta*
70 g.
|
Samaghe Arabi
*Acacia arabica (lam.)*
5 g.
|
Rubus Soos
*Glycyrrhiza glabra Linn.*
5 g.
|
Maghz e Chilghoza
*Pinus gerardiana*
5 g.
|
Mastagi
*Pistacia lentiscus Linn*
5 g.
|
Darchini
*Cinnamomum verum*
5 g.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- All
- Target Recruitment
- 240
- Subjects of either sex between the age group of 18-65 years.
- Subjects of Bronchial Asthma for at least 6 months presenting with at least one of the following symptoms: Wheeze Shortness of breath Chest tightness and cough that vary over time and in intensity, Expiratory airflow limitation as suggested by a decreased FEV1 3.
- Objective evidence for reversible airway obstruction (≥12% and ≥200 mL change in FEV1 and/or a 25% and 60 L/min change in PEFR) either spontaneously or after treatment.
- Subjects with Asthma Control Questionnaire Score > 1.5.
- FEV1/FVC ratio < 50% 2.
- Pregnant and lactating females 3.
- Subjects with other Respiratory Tract Infections, tuberculosis and malignancy.
- Subjects with co-morbidities; Diabetes Mellitus, Hepatic and Renal Insufficiency 5.
- Subjects with known interstitial lung disease.
- Subjects with Tobacco Smoking.
- Subjects with known chronic obstructive pulmonary disease (COPD) 8.
- Patient with regular use of oral or systemic corticosteroids for conditions other than Asthma.
- Subjects who are not willing to participate in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in sign and symptoms of Zeeq un Nafas (Bronchial asthma) on the basis of Asthma Control Questionnaire (ACQ), Pulmonary Function Test:FEV1, FEV1/FVC ratio, PEFR by Spirometry,Absolute Eosinophil Count(AEC) At week 1, 2, 3 and 4
- Secondary Outcome Measures
Name Time Method Haematological and biochemical assessment for safety assessment At baseline and after 4 weeks
Trial Locations
- Locations (1)
Regional Research Institute of Unani Medicine, Mumbai
🇮🇳Mumbai, MAHARASHTRA, India
Regional Research Institute of Unani Medicine, Mumbai🇮🇳Mumbai, MAHARASHTRA, IndiaDr Shah AlamPrincipal investigator7008498476shahccrum@gmail.com